Actin Monomers Activate Inverted Formin 2 by Competing with Its Autoinhibitory Interaction
Overview
Affiliations
INF2 is an unusual formin protein in that it accelerates both actin polymerization and depolymerization, the latter through an actin filament-severing activity. Similar to other formins, INF2 possesses a dimeric formin homology 2 (FH2) domain that binds filament barbed ends and is critical for polymerization and depolymerization activities. In addition, INF2 binds actin monomers through its diaphanous autoregulatory domain (DAD) that resembles a Wiskott-Aldrich syndrome protein homology 2 (WH2) sequence C-terminal to the FH2 that participates in both polymerization and depolymerization. INF2-DAD is also predicted to participate in an autoinhibitory interaction with the N-terminal diaphanous inhibitory domain (DID). In this work, we show that actin monomer binding to the DAD of INF2 competes with the DID/DAD interaction, thereby activating actin polymerization. INF2 is autoinhibited in cells because mutation of a key DID residue results in constitutive INF2 activity. In contrast, purified full-length INF2 is constitutively active in biochemical actin polymerization assays containing only INF2 and actin monomers. Addition of proteins that compete with INF2-DAD for actin binding (profilin or the WH2 from Wiskott-Aldrich syndrome protein) decrease full-length INF2 activity while not significantly decreasing activity of an INF2 construct lacking the DID sequence. Profilin-mediated INF2 inhibition is relieved by an anti-N-terminal antibody for INF2 that blocks the DID/DAD interaction. These results suggest that free actin monomers can serve as INF2 activators by competing with the DID/DAD interaction. We also find that, in contrast to past results, the DID-containing N terminus of INF2 does not directly bind the Rho GTPase Cdc42.
Albaghdadi A, Xu W, Kan F Int J Mol Sci. 2024; 25(22).
PMID: 39596157 PMC: 11593602. DOI: 10.3390/ijms252212090.
Regulation of formin INF2 and its alteration in INF2-linked inherited disorders.
Labat-de-Hoz L, Jimenez M, Correas I, Alonso M Cell Mol Life Sci. 2024; 81(1):463.
PMID: 39586895 PMC: 11589041. DOI: 10.1007/s00018-024-05499-3.
INF2 mutations cause kidney disease through a gain-of-function mechanism.
Subramanian B, Williams S, Karp S, Hennino M, Jacas S, Lee M Sci Adv. 2024; 10(46):eadr1017.
PMID: 39536114 PMC: 11559609. DOI: 10.1126/sciadv.adr1017.
Tran Q, Kondo N, Ueda H, Matsuo Y, Tsukaguchi H Int J Mol Sci. 2024; 25(18).
PMID: 39337270 PMC: 11431639. DOI: 10.3390/ijms25189783.
Labat-de-Hoz L, Fernandez-Martin L, Correas I, Alonso M Cell Mol Life Sci. 2024; 81(1):279.
PMID: 38916773 PMC: 11335204. DOI: 10.1007/s00018-024-05323-y.